Navigation Links
New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C)

of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional.

In clinical trials for Chronic Idiopathic Constipation (24 mcg BID), the most common adverse event was nausea (31%). Other adverse events (greater than or equal to 5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%).

    For full prescribing information, visit www.amitiza.com.

    AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., is an emerging pharmaceutical company based in Bethesda, Md. Sucampo Pharmaceuticals was founded in 1996 by Sachiko Kuno, Ph.D., the company's President and Chair of the Board of Directors, and Ryuji Ueno, M.D., Ph.D., Ph.D., the company's Chief Executive Officer and Chief Scientific Officer. Sucampo Pharmaceuticals focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Dr. Ueno. In January 2006, Sucampo Pharmaceuticals received marketing approval from the FDA for its first product, AMITIZA, for the treatment of Chronic Idiopathic Constipation in adults. In October 2004, Sucampo Pharmaceuticals entered into an agreement with Takeda Pharmaceutical Company Limited (Osaka, Japan) to co- promote and market AMITIZA in the United States and Canada. Sucampo Pharmaceuticals' specialized sales force complements the efforts of Takeda by focusing on institutional and long-term care facilities. To learn more about the company and its products, visit www.sucampo.com.

Takeda Pharmaceuticals North America, I
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/25/2009)...LEGE PARK, Md., Nov. 25 ...a shaving cream-like foam that stops severe bleedi...ing Security Idea category of the Global Security ...,, Selected from more than 100 entries from aro...tion at the GSC Security Summit conference held at...
(Date:11/25/2009)...ING RIDGE, N.J., Nov. 25 Regado Bi...velopment of antithrombotic aptamers with active c...O and President, will be presenting at the Piper J...ew York Palace Hotel in New York City. Dr. Mazzo,...esday, December 1 and will include an overview of ...
(Date:11/25/2009)... NEW YORK, Nov. 25 Reportlinker.co...vailable in its catalogue: ,, United States De... ,, http://www.reportlinker.com/p0158733/Unit...asts-to-2015.html ,, United States Dental Devi...ummary ,, This report is an essential source f...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Industry Veteran Stephen Duvall Joins Millennium Management Team 48615 1Industry Veteran Stephen Duvall Joins Millennium Management Team 48615 2SmallCapSentinel com Releases Market Actives List for JAZZ MEXP C SAY GOOG AAPL 48610 1SmallCapSentinel com Releases Market Actives List for JAZZ MEXP C SAY GOOG AAPL 48610 2The microbial hydrocarbon diet 48605 1The microbial hydrocarbon diet 48605 2
...osenberg, CEO of the International Partnership for...he results of the Phase II/IIb safety and effectiv...concentration): , , SILVER SPRING, Md., Feb. 9 T...rative group funded by the US National Institutes ...se II/IIb safety and effectiveness study of two mi...
...SHINGTON, Feb. 6 The U.S. Agency for Internatio...tance to the people of Zimbabwe, who are in the mi... economy, food shortages and the cholera epidemic ...r health risks. , , USAID, through the Presiden...door Residual Spraying (IRS) to shore up gaps in t...
Other Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4USAID Provides Malaria Assistance to Zimbabwe 2
(Date:11/27/2009)...ti-purpose bilingual coloring books designed for c...ness community to educate - inform parents and chi...ssues to Dinosuars to ABC,S and a host of other to...PRWEB) November 27, 2009 -- Today’s children...them busy any hour of the day, but one of the olde...
(Date:11/26/2009)..., Nov. 27 The diabetes population ...ext 25 years and annual medical spending on the di...13 billion today, according to a study published i...onal Changing Diabetes ® Program (NCDP), a p...by a team from the University of Chicago. ,, Ac...
(Date:11/26/2009)... on an emotional rollercoaster, study finds , ... it the fear factor meets the jubilant sports fan....cially those who root for the winning team -- enjo...ested match and victory was in doubt, producing fe...t this Thanksgiving weekend as you,re glued to the...
(Date:11/26/2009)...ton Communications announces a highly effective an...ers struggling to make an economic recovery. , ... Flu fears is the type of challenge that could sen...rding to Dr. David Benton, business growth expert ...ystem – The Rfactor Intensive . “Fe...
(Date:11/25/2009)...if., Nov. 25 Onyx Phar... that the company will host two investor events in...r 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,, Pri...ns surrounding carfilzomib in relapsed and/or refr...merican Society of Hematology (ASH) Annual Meeting...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...headlines were attention-grabbing. Discovery News ...The website NowPublic wrote "FDA Certifies Handgun...lf "the internet journal of emerging medical techn...mericans that will be subsidi[z]ed by the governme...
...eade Holdings, Inc. today announced the appointmen...ident of Pharmacy Operations effective December 1,...derer, Chairman and Chief Executive Officer. His ...or executives. , , Mr. John Lederer, Chairma...
... Rowland K. Robinson, president of Baylor Health C... Y. Davis, Shareholder Advocate, and the Evelyn Y....ft to support Riggs Emergency Department at Baylo...to Evelyn for her support and magnanimity," said R...
.... 8 Warner Chilcott Limited (Nasdaq: WCRX ) ann...s and Hospira, Inc. ("Hospira") have received Para...eutical Company, Inc. ("Mutual") and Mylan Pharmac...mg delayed-release tablets. , , DORYX, which...
...enkins, M.D., accomplished Hawaii,ophthalmologist ...ss magazine,2009 Small Business Success Award. , ... many ways: professional,trailblazer, health care ...y and remains on top of technological,advances in ...
...pital may be a contributing cause, study suggests ...en who suffer the most severe form of heart attack..., a new study finds. , The study of more than 78,0... 10.2 percent of women with a STEMI heart attack d...
Other Medicine News:Health News:A Good Cigar May Be a Smoke, But a Gun Is Not a Medical Device, FDA Says in Response to Gunmaker 2Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 2Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 3Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 2Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 3Health News:Hawaii Eye Surgeon Receives Small Business Success Award 2Health News:Women's Death Rate Higher From Severe Heart Attack 2Health News:Women's Death Rate Higher From Severe Heart Attack 3
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: